CERTIFICATES
Good Manufacturing Practices Certificate
Good Laboratory Practices Certificate
Certificate of Compliance
ISO 9001-2015 Certificate
A SUCCESS STORY
The Pharmaceutical sector is one where trends and technologies are in a state of flux. New breakthroughs in the world and Healthcare occur at a frantic pace. This demands for expertise and skill to stay ahead.
Unijules Life Sciences Ltd. exemplifies an organisation displaying these very traits.
Headquartered and set-up in the industrial belt of Nagpur City of Central India, UNIJULES, Injectable has established itself as one of the preferred diagnostic products solution providers in the field of Radiological Diagnosis. The first iodinated ionic contrast product Uroscan 76 was developed in 1998 and till now it is marketed as an affordable and effective iodinated ionic contrast product, yet offers newer molecules such as the iodinated non ionic contrast and gadolinium based products to the common man.
The recently developed premix formulations and technology transfer modules of business will pave the future.
All sites of UNIJULES are supported by an excellent technical team and sufficient capacity to produce large requirements for different market segments.
Of the UNIJULES Group Companies, the Injectable Division at D-82 Hingna, Nagpur is engaged in the activity of manufacturing, distributing, contract manufacturing a range of liquid injectables.
The division has two sections of manufacturing. One is the Small volume Parentrals and second is the Large volume parenterals, both of which are WHO-GMP certified, geared up for both domestic and export market production.
The basket of injectable products includes a range of niche products - contrast media used for radiological diagnostic purposes. These products are iodinated, ionic and non-ionic, commonly referred to as Iodinated contrast media or ICM having their scope of use in Computed tomography CT scanning. Also manufactured are gadolinium based contrast media referred to as GBCA being used in Magnetic Resonance Imaging or MRI scanning.
The presence of an iodinated oral contrast solution for the viewing of the GI tract, is also in the range of products.
Other injectables are also manufactured on the premises such as anaesthetics, antihypertensives, Iron supplements, vitamins to name a few.
The specific scope of these products, a few manufacturers and with our products quality and effectiveness have ensured a strong presence in both domestic and international markets.
OUR VISION
We believe that the pharmaceutical business is today poised for a great leap forward. Truly innovative technologies with the potential to change the nature of human health and longevity have already appeared and each day brings better and better innovations. At the same time, the fruits of these discoveries are becoming prohibitively unaffordable for the majority of the human race. There is a desperate need for solutions that emerge out of these innovative technologies to reach the common man at an affordable cost so that these benefits do not remain accessible only to the rich and affluent sections of society.
Ever changing regulatory guidelines, advances in drug therapy and delivery systems, drug industry mergers, acquisitions, globalisation and evolving markets such as those for diagnostic purposes pose challenges to every pharmaceutical organisation to manage and accelerate the drug development process.
We, at UNIJULES, aspire to play a significant role in making the fruits of such technologies available as affordable healthcare solutions, teaming with like-minded associates in the pharmaceutical technology business, aiming for customer satisfaction, while respecting the rights of others.
Uniquely positioned to provide & expertise in niche products, we support our own and customers objectives with specialised formulations to reach the market faster and easier than ever. We are committed towards providing our national and international clients an easy and timely access to sophisticated process technologies and products, give value for money and to offer our customer innovative and exclusive quality products that differentiate them from their competitors and significantly impacts their bottom line. That's why, every day we continue to put our zeal for excellence and spirit of innovation into all our actions.
FORMULATION AND DEVELOPMENT
1. Formulation development will continue to be the benchmark of growth, a way forward and success. Need of the hour, niche formulations have already been identified for development.
2. The benefits derived are...- Being unique, the margins are much above the industry standards.
- Since very few players, this situation drives commercialization of common products thus tying up capacities and bringing in the required job work equivalent.
- Cost cutting by changing formulations, yet maintaining their effectiveness and quality.
- Generation of stability data to validate its integrity.
- International recognition as quality service provider.
3. Future Plan of Action
- Development of New molecules in iodinated and gadolinium molecules for specific organ diagnosis.
- Major thrusts towards other dosage forms such as lyophilized products, dry powder fills, Prefilled syringes so as to compete in the ever-evolving markets.
- New plants to increase existing capacities as well as introduce new ranges in Parenterals such as Premixes.
